文献速递头颈与中枢神经肿瘤

托泊替康慢性对流增强递送治疗复发胶质母细胞瘤:首例患者、单中心、单臂、1b期试验

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
PubMed 文献 · Lancet Oncol · 2022-10-13

在单中心、开放标签、单臂1b期试验中,5例复发胶质母细胞瘤患者接受皮下植入导管泵系统进行托泊替康慢性对流增强递送,4次输注后手术切除肿瘤。治疗耐受良好,仅1例(20%)出现与治疗相关的3级不良事件,无4级不良事件;治疗后组织分析显示托泊替康显著减少所有5例患者的增殖肿瘤细胞。作者认为该疗法可能安全有效,但需进一步研究确定其对临床结局的影响。

要点

  • 慢性对流增强递送托泊替康在5例复发胶质母细胞瘤患者中安全完成,耐受良好。
  • 唯一与治疗相关的3级不良事件为术中辅助运动区综合征(1/5,20%),无4级不良事件。
  • 治疗后组织分析显示托泊替康显著减少所有5例患者的增殖肿瘤细胞。

核心结论

  • 作者认为,慢性对流增强递送托泊替康是复发胶质母细胞瘤可能安全且有活性的疗法。
  • 作者指出,该分析提供了无需大样本量的独特组织学疗效评估。
  • 作者认为,这种新型托泊替康递送方式克服了胶质母细胞瘤患者递送和疗效评估的局限性,可能适用于其他抗胶质瘤药物或其他中枢神经系统疾病。
  • 作者建议,需进一步研究以确定该药物递送方式对临床结局的影响。

研究设计与样本

  • 单中心、开放标签、单臂1b期临床试验,在哥伦比亚大学欧文医学中心(美国纽约州纽约市)进行。
  • 纳入标准:年龄至少18岁,组织学确诊的孤立复发胶质母细胞瘤,术后、放疗和化疗后影像学进展,卡氏功能状态评分至少70。
  • 5例患者经立体定向将导管植入胶质瘤浸润的瘤周脑组织,连接皮下植入泵,以200 μL/h输注146 μM托泊替康48小时,随后5-7天洗脱期,共4次输注;第4次输注后移除泵并切除肿瘤。
  • 主要终点为治疗方案的按严重不良事件定义的安全性;分析纳入所有治疗患者。
  • 试验已关闭,注册号ClinicalTrials.gov NCT03154996。

主要发现

  • 2018年1月22日至2019年7月8日期间,5例患者均安全完成慢性对流增强递送托泊替康,耐受良好,无重大并发症。
  • 唯一与治疗相关的3级不良事件为术中辅助运动区综合征(治疗组5例中1例[20%]),无4级不良事件。
  • 其他严重不良事件与手术切除相关,而非研究治疗。
  • 从泵移除后中位随访12个月(IQR 10-17)。
  • 治疗后组织分析显示,托泊替康显著减少所有5例患者的增殖肿瘤细胞。

关键数值与推荐

  • 托泊替康输注浓度146 μM,速率200 μL/h,持续48小时,洗脱期5-7天,共4次输注。
  • 唯一与治疗相关的3级不良事件为术中辅助运动区综合征(1/5,20%),无4级不良事件。
  • 中位随访12个月(IQR 10-17),从泵移除后计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出本研究为小样本患者队列。
  • 作者建议需进一步研究以确定该药物递送方式对临床结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topotecan is cytotoxic to glioma cells but is clinically ineffective because of drug delivery limitations. Systemic delivery is limited by toxicity and insufficient brain penetrance, and, to date, convection-enhanced delivery (CED) has been restricted to a single treatment of restricted duration. To address this problem, we engineered a subcutaneously implanted catheter-pump system capable of repeated, chronic (prolonged, pulsatile) CED of topotecan into the brain and tested its safety and biological effects in patients with recurrent glioblastoma. METHODS: We did a single-centre, open-label, single-arm, phase 1b clinical trial at Columbia University Irving Medical Center (New York, NY, USA). Eligible patients were at least 18 years of age with solitary, histologically confirmed recurrent glioblastoma showing radiographic progression after surgery, radiotherapy, and chemotherapy, and a Karnofsky Performance Status of at least 70. Five patients had catheters stereotactically implanted into the glioma-infiltrated peritumoural brain and connected to subcutaneously implanted pumps that infused 146 μM topotecan 200 μL/h for 48 h, followed by a 5-7-day washout period before the next infusion, with four total infusions. After the fourth infusion, the pump was removed and the tumour was resected. The primary endpoint of the study was safety of the treatment regimen as defined by presence of serious adverse events. Analyses were done in all treated patients. The trial is closed, and is registered with ClinicalTrials.gov, NCT03154996. FINDINGS: Between Jan 22, 2018, and July 8, 2019, chronic CED of topotecan was successfully completed safely in all five patients, and was well tolerated without substantial complications. The only grade 3 adverse event related to treatment was intraoperative supplemental motor area syndrome (one [20%] of five patients in the treatment group), and there were no grade 4 adverse events. Other serious adverse events were related to surgical resection and not the study treatment. Median follow-up was 12 months (IQR 10-17) from pump explant. Post-treatment tissue analysis showed that topotecan significantly reduced proliferating tumour cells in all five patients. INTERPRETATION: In this small patient cohort, we showed that chronic CED of topotecan is a potentially safe and active therapy for recurrent glioblastoma. Our analysis provided a unique tissue-based assessment of treatment response without the need for large patient numbers. This novel delivery of topotecan overcomes limitations in delivery and treatment response assessment for patients with glioblastoma and could be applicable for other anti-glioma drugs or other CNS diseases. Further studies are warranted to determine the effect of this drug delivery approach on clinical outcomes. FUNDING: US National Institutes of Health, The William Rhodes and Louise Tilzer Rhodes Center for Glioblastoma, the Michael Weiner Glioblastoma Research Into Treatment Fund, the Gary and Yael Fegel Foundation, and The Khatib Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Spinazzi EF, Argenziano MG, Upadhyayula PS, et al. Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. Lancet Oncol. 2022. PMID: 36243020. doi:10.1016/S1470-2045(22)00599-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。